Boussetta, Sami
Mayo Clinic
The Lymphoma Academic Research Organisation
Citations 2
Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study.
Crump, Michael , Neelapu, Sattva S. , Neste, Éric Van Den, Ahmed, Mohamed , Zhu, Liting , Feng, Lei, Navale, Lynn, Wiezorek, Jeffrey S., Go, William Y., Gisselbrecht, Christian , Farooq, Umar , Kuruvilla, John , Link, Brian K. , Hay, Annette E. , Cerhan, James R. , Boussetta, Sami , Maurer, Matthew J.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7516-7516
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, Michael , Neelapu, Sattva S. , Farooq, Umar , Neste, Éric Van Den, Westin, Jason R. , Link, Brian K. , Hay, Annette E. , Zhu, Liting , Navale, Lynn, Wiezorek, Jeff, Go, William Y., Gisselbrecht, Christian , Link, Brian K , Farooq, Umar , Westin, Jason R , Kuruvilla, John , Cerhan, James R. , Boussetta, Sami , Feng, Lei , Maurer, Matthew J.
Blood | August 3, 2017 | Volume: 130 | Issue: 16 | Pages: 1800-1808
Key Points SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases. SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.